Deceleration capacity of heart rate predicts trastuzumab‐related cardiotoxicity in patients with HER2‐positive breast cancer: A prospective observational study.
What is known and objectives: Trastuzumab is the standard choice for anti‐human epidermal growth factor receptor 2 (HER2) therapy. Cardiotoxicity is one of the main adverse effects of trastuzumab. How to early predict trastuzumab‐related cardiotoxicity remains a significant problem in clinical pract...
| Publicado en: | Journal of Clinical Pharmacy & Therapeutics Vol. 46; no. 1; pp. 93 - 99 |
|---|---|
| Autores principales: | , , |
| Formato: | research tables/charts Journal Article |
| Publicado: |
Wiley-Blackwell
Feb2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |